November 25, 2013

Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

This study provides a rationale to test AZD3965 in patients with SCLC. Our results suggest that patients with tumors expressing MCT1 and lacking in MCT4 are most likely to respond.

Perguntar à IA

Bookmark

Cite This Study

Polański et al. (Mon,) studied this question.

synapsesocial.com/papers/69d6d7e98dca315383ed939d https://doi.org/https://doi.org/10.1158/1078-0432.ccr-13-2270

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Adjuvant and neoadjuvant therapy in prostate cancer2001 · 35 citations
2Treatment of recurrent small cell lung cancer2004 · 27 citations
3A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells2009 · 1,044 citations
4Targeting HIF-1 for cancer therapy2003 · 6,709 citations
5Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database2006 · 1,854 citations

Perguntar à IA

Bookmark